Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
UNIVASC (moexipril hydrochloride) is an oral ACE inhibitor prodrug approved in 1995 for hypertension management. It works by inhibiting angiotensin-converting enzyme (ACE), reducing angiotensin II formation and lowering blood pressure through decreased vasoconstriction and aldosterone secretion. The drug is a small-molecule tablet with established efficacy, though effectiveness is notably lower in Black patients due to population-level differences in renin-angiotensin system activity.
Approaching loss of exclusivity with moderate competitive pressure (30/100), indicating contraction phase with reduced investment in brand expansion and team growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on UNIVASC offers limited career advancement opportunities given the product's LOE-approaching lifecycle and zero linked job openings. Roles focus on defending market share, managing generic transition, and optimizing existing patient populations rather than growth initiatives.
Worked on UNIVASC at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.